focus -WSS

focus

author：knowledge 2025-09-30 18:17:23 - browse：134

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Failure, not just success, should guide future doctors

knowledge

WSS

Ebola public health emergency is over, WHO declares

India sets sights on home

St. Louis police protesters begin picking up checks in $4.9 million settlement

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Seattle police shoot person suspected in downtown stabbing

Election results set back Medicaid expansion plans

leisure time

focus

hotspot

Heart attack and stroke risk calculators need revising

Seattle police shoot person suspected in downtown stabbing

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Many breast cancer patients receive more radiation than needed

Apple is now the first public company to be valued at $3 trillion

Restaurant meals are packed with calories, and we still keep eating them

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Doctors push to include dialysis machines in emergency stockpile

BioMarin wins approval for gene therapy to treat hemophilia A

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Wikipedia

How dance can help health care workers heal from trauma

Many breast cancer patients receive more radiation than needed

'Brian's Song' at 50 still offers lessons about cancer for today

Man who had jail sentence commuted by Trump arrested again

Slovenia has suffered its worst

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

entertainment

knowledge

leisure time

entertainment